Sienna Announces Changes To Management Team

  • Dr Cliff Holloway to stand down as CEO and Managing Director
  • Mr Carl Stubbings appointed Interim CEO
Sienna Cancer Diagnostics today announces Dr Cliff Holloway has resigned his position as CEO and Managing Director, to pursue a new career opportunity. Dr Holloway has accepted a senior executive position based in the USA, with a NASDAQ listed Biotechnology Company.

Sienna’s Non-executive Director, Carl Stubbings, has been appointed as interim CEO.  Dr Holloway will continue to work with Mr Stubbings and Sienna’s management team, to assist in a smooth transition.  Mr Stubbings has been a Non-executive Director of the company since 2011, and has held senior leadership and sales & marketing roles in the biotechnology and diagnostics industries. He was previously the Vice President of Sales and Marketing at Focus Diagnostics Inc., a subsidiary of Quest Diagnostics.  Mr Stubbings is also a Non-executive Director at Analytica Ltd and Otakaro Pathways.

Sienna’s Chairman Dr Geoff Cumming noted, “Over the last 18 months Dr Holloway’s leadership leaves the company in an excellent position to execute our near term goals.  We thank Cliff for his contribution to the company’s development”.

Sienna remains on track to achieve its goal of launching an In-Vitro Diagnostic (IVD) by the end of the calendar year 2016.


No Very

Captcha Image

Sign up for updates